Jon Ukropec

4.2k total citations
44 papers, 1.2k citations indexed

About

Jon Ukropec is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Jon Ukropec has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 20 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Jon Ukropec's work include Multiple Myeloma Research and Treatments (37 papers), Peptidase Inhibition and Analysis (14 papers) and Synthesis and Biological Evaluation (12 papers). Jon Ukropec is often cited by papers focused on Multiple Myeloma Research and Treatments (37 papers), Peptidase Inhibition and Analysis (14 papers) and Synthesis and Biological Evaluation (12 papers). Jon Ukropec collaborates with scholars based in United States, Spain and France. Jon Ukropec's co-authors include Meletios Α. Dimopoulos, Nizar J. Bahlis, Ming Qi, Annette Lam, Jianming He, Sarah Côté, Lotfi Benboubker, Xiang Qin, Philippe Moreau and María‐Victoria Mateos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jon Ukropec

41 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jon Ukropec United States 17 1.1k 731 665 198 95 44 1.2k
Karthik Ramasamy United Kingdom 18 918 0.9× 788 1.1× 614 0.9× 147 0.7× 81 0.9× 142 1.2k
Cristina Gasparetto United States 19 776 0.7× 656 0.9× 561 0.8× 138 0.7× 124 1.3× 93 1.1k
Huaibao Feng United States 13 1.1k 1.1× 859 1.2× 796 1.2× 229 1.2× 112 1.2× 30 1.4k
Himal Amin United States 8 1.1k 1.0× 870 1.2× 685 1.0× 197 1.0× 113 1.2× 13 1.4k
Claudius Rudin United Kingdom 7 500 0.5× 352 0.5× 532 0.8× 73 0.4× 92 1.0× 16 845
Halyna Pylypenko Czechia 11 747 0.7× 736 1.0× 672 1.0× 389 2.0× 20 0.2× 29 1.3k
Kelly Godby United States 11 695 0.7× 501 0.7× 435 0.7× 99 0.5× 43 0.5× 52 789
Pamela L. Clemens United States 15 557 0.5× 329 0.5× 468 0.7× 134 0.7× 191 2.0× 33 803
Nathan Petty United States 16 1.2k 1.1× 955 1.3× 681 1.0× 161 0.8× 54 0.6× 29 1.3k
Anita Zahlten‐Kumeli United States 11 826 0.8× 711 1.0× 548 0.8× 97 0.5× 39 0.4× 24 995

Countries citing papers authored by Jon Ukropec

Since Specialization
Citations

This map shows the geographic impact of Jon Ukropec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Ukropec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Ukropec more than expected).

Fields of papers citing papers by Jon Ukropec

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Ukropec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Ukropec. The network helps show where Jon Ukropec may publish in the future.

Co-authorship network of co-authors of Jon Ukropec

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Ukropec. A scholar is included among the top collaborators of Jon Ukropec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Ukropec. Jon Ukropec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Crombie, Jennifer L., Tongsheng Wang, Anthony Wang, et al.. (2024). Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 65(11). 1623–1633. 1 indexed citations
2.
Crombie, Jennifer L., et al.. (2023). REAL‐WORLD OUTCOMES WITH NOVEL THERAPIES IN R/R DLBCL. Hematological Oncology. 41(S2). 719–720.
3.
Crombie, Jennifer L., et al.. (2023). Real-world outcomes with novel therapies in R/R DLBCL.. Journal of Clinical Oncology. 41(16_suppl). 7552–7552.
4.
Cook, Gordon, Alessandro Corso, Matthew Streetly, et al.. (2021). Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. Oncology and Therapy. 9(1). 139–151. 6 indexed citations
5.
Voorhees, Peter M., Cesar Rodriguez, Brandi Reeves, et al.. (2021). Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Advances. 5(4). 1092–1096. 18 indexed citations
6.
Xu, Xu Steven, Philippe Moreau, Saad Z. Usmani, et al.. (2020). Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Advances in Therapy. 37(4). 1464–1478. 9 indexed citations
7.
Fonseca, Rafaël, Saad Z. Usmani, Maneesha Mehra, et al.. (2020). Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 20(1). 1087–1087. 67 indexed citations
8.
Bahlis, Nizar J., Meletios Α. Dimopoulos, Darrell White, et al.. (2020). Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 34(7). 1875–1884. 158 indexed citations
9.
Mateos, María‐Victoria, Pieter Sonneveld, Vânia Hungria, et al.. (2019). Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma Myeloma & Leukemia. 20(8). 509–518. 93 indexed citations
10.
Weisel, Katja, Pieter Sonneveld, María‐Victoria Mateos, et al.. (2019). Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor. Blood. 134(Supplement_1). 3192–3192. 26 indexed citations
11.
Kaufman, Jonathan L., Saad Z. Usmani, Jesús F. San Miguel, et al.. (2019). Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 1866–1866. 28 indexed citations
12.
Mateos, María‐Victoria, Andrew Spencer, Ajay K. Nooka, et al.. (2019). Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 105(2). 468–477. 43 indexed citations
13.
14.
15.
Caplan, Arthur L., et al.. (2018). A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC). Therapeutic Innovation & Regulatory Science. 53(2). 243–248. 8 indexed citations
16.
Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2018). Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM). Blood. 132(Supplement 1). 152–152. 9 indexed citations
17.
Chari, Ajai, Sagar Lonial, Tomer M. Mark, et al.. (2018). Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer. 124(22). 4342–4349. 27 indexed citations
18.
19.
20.
Terpos, Evangelos, Meletios Α. Dimopoulos, Efstathios Kastritis, et al.. (2017). A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO. Annals of Oncology. 28. v368–v369. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karthik Ramasamy Breakdown of academic impact, for papers by Cristina Gasparetto Breakdown of academic impact, for papers by Huaibao Feng Breakdown of academic impact, for papers by Himal Amin Breakdown of academic impact, for papers by Claudius Rudin Breakdown of academic impact, for papers by Halyna Pylypenko Breakdown of academic impact, for papers by Kelly Godby Breakdown of academic impact, for papers by Pamela L. Clemens Breakdown of academic impact, for papers by Nathan Petty Breakdown of academic impact, for papers by Anita Zahlten‐Kumeli
Rankless by CCL
2026